TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24147745
Drug: gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel with 2% sodium fluoride (n=17)
Study: 24147745
Drug: gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel with 10% CPP‐ACP (n=17)
Study: 22336530
Drug: Conventional antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antimicrobial treatment (non-de-escalation, NDE)
Study: 19047297
Drug: Adjuvant goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant goserelin after radiation therapy (RT)
Study: 11408151
Drug: Loperamide-simethicone combination
Normalized name: loperamide / simethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide-simethicone combination formulation
Study: 2163253
Drug: Soy cotyledon
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy cotyledon fiber supplementation (15 grams per day in three divided doses)
Study: 892352
Drug: Salt and
Normalized name: ZINC OXIDE 240 mg in 1 g TOPICAL STICK [Salt and Stone Outdoor Voices SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt and water restriction plus diuretics
Study: 30829779
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum (CCH) 0.84 mg
Study: 24861902
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral caffeine intake
Study: 23237127
Drug: Attention-control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-control group (supportive therapy)
Study: 15516290
Drug: 25 microg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 microg/h F transdermal patches (N = 142)
Study: 15516290
Drug: 50 microg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg/h F transdermal patches (N = 184)
Study: 15516290
Drug: 75 microg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 microg/h F transdermal patches (N = 85)
Study: 15516290
Drug: 100 microg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg/h F transdermal patches (N = 135)
Study: 9722255
Drug: Systemic and
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic and inhaled saline
Study: 3058630
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of steroids (32 mg of oral methylprednisolone, approximately 2 hours before CM challenge)
Study: 3058630
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of steroids (32 mg approximately 12 hours and 2 hours before CM challenge)
Study: 22124795
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg Cu/d (supplemented group, SG)
Study: 19561530
Drug: mesalazine scheduled
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mesalazine scheduled daily
Study: 12192167
Drug: DTPa-HepB combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HepB combination vaccine
Study: 12192167
Drug: Monovalent HepB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent HepB vaccine
Study: 9655370
Drug: DHA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA group (7 subjects) - 6 g DHA/d for 90 days after a basal diet for 30 days
Study: 2592587
Drug: Velnacrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine (100 mg) administered after an overnight fast
Study: 2592587
Drug: Velnacrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine (100 mg) administered 15 minutes after a standard breakfast
Study: 22936319
Drug: Synchronized therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronized therapy group (I-125 seeds implantation combined with chemotherapy and Chinese medicine)
Study: 22936319
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus CM-treated group
Study: 22936319
Drug: Chemotherapy-treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-treated group
Study: 18926641
Drug: Monoamine reuptake
Normalized name: Non-selective monoamine reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine reuptake inhibitors
Study: 17632217
Drug: Quetiapine, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine, 400 mg/d at bedtime
Study: 14767152
Drug: Multimodal cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cognitive-behavioral therapy (CBT)
Study: 11396366
Drug: Dose-dense, dose-intense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense, dose-intense EC‐>T (epirubicin, cyclophosphamide, followed by paclitaxel)
Study: 2826098
Drug: Raw wheat
Normalized name: Potassium/Wheat Germ 250 MG Oral Powder [NATURFRESH RAW WHEAT GERM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw wheat whole-meal preparation
Study: 2826098
Drug: Heated wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated wheat and corn whole-meal preparations
Study: 31915255
Drug: Tiagabine (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (oral, 10 mg)
Study: 28348720
Drug: EMDR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR therapy carried out by a psychologist
Study: 23903476
Drug: Topical 0.03%
Normalized name: tacrolimus topical 0.03% topical ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.03% budesonide rinse
Study: 23903476
Drug: Topical 0.01%
Normalized name: tretinoin topical 0.01% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.01% dexamethasone rinse
Study: 21098871
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 3 months
Study: 8334888
Drug: Triphasic combined
Normalized name: Tribasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic combined oral contraceptive
Study: 8334888
Drug: Low-dose monophasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monophasic combined oral contraceptive
Study: 24621680
Drug: N-acetylcysteine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 600 mg twice daily
Study: 20642691
Drug: EPO-beta (30,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO-beta (30,000 UI each) administered before surgery and at 12 h, 7 days, and 14 days posttransplantation.
Study: 20642691
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no EPO-beta treatment).
Study: 15918388
Drug: i.v. remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. remifentanil PCA (loading dose: 45 microg, maintenance dose: 1 microg min(‐1), bolus dose: 15 microg, lockout interval: 10 min)
Study: 15918388
Drug: i.v. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. morphine PCA (loading dose: 5 mg, maintenance dose: 0.3 mg h(‐1), bolus dose: 1 mg, lockout interval: 15 min)
Study: 11448655
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg + sulfonylurea
Study: 11448655
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg + sulfonylurea
Study: 465179
Drug: Cholestyramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine plus usual treatment (rehydration, refeeding, furazolidone)
Study: 465179
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (rehydration, refeeding, furazolidone)
Study: 28809658
Drug: Cognitive-Functional (Cog-Fun)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Functional (Cog-Fun) occupational therapy intervention
Study: 17151159
Drug: Switching antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching antipsychotics
Study: 19725969
Drug: Initial antipsychotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antipsychotic therapy
Study: 17563126
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg plus paracetamol 500 mg
Study: 11403726
Drug: Baclofen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (20 mg)
Study: 9951580
Drug: Chemotherapy including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Chemotherapy including doxorubicin and/or cyclophosphamide
Study: 9951580
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without doxorubicin and/or cyclophosphamide
Study: 17617528
Drug: Single-agent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent cisplatin
Study: 8091240
Drug: Platinum-based multiagent
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based multiagent chemotherapy
Study: 3292601
Drug: Superactivated charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superactivated charcoal (20 g twice daily)
Study: 30912806
Drug: Combined GH/GnRHa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined GH/GnRHa therapy
Study: 30912806
Drug: Prepubertal status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepubertal status at onset of GH treatment
Study: 28830024
Drug: Cognitive exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive exercise therapy (CET) in addition to cognitive-behavioral therapy (CBT) and graded exercise therapy (GET)
Study: 28830024
Drug: Cognitive exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive exercise therapy (CET)
Study: 28830024
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and graded exercise therapy (GET) alone
Study: 25638341
Drug: Individualized hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized hormone adjustment (estrogen, progesterone, and luteinizing hormones)
Study: 21522037
Drug: Motavizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motavizumab (15 mg/kg, five monthly doses)
Study: 21522037
Drug: Palivizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab (15 mg/kg, five monthly doses)
Study: 19883270
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g glucose (placebo)
Study: 16534469
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (no therapy)
Study: 7528560
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (2 million IU before CPB, 500,000 IU/h until end of operation, 2 million IU added to the prime) (N = 20)
Study: 2921600
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 50 mg/day
Study: 2921600
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 100 mg/day
Study: 25446610
Drug: RT with
Normalized name: NuCort with Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT with capecitabine (1200 mg/m²/d Monday‐Friday) plus irinotecan (50 mg/m²/wk × 4)
Study: 25446610
Drug: RT with
Normalized name: NuCort with Aloe
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT with capecitabine (1650 mg/m²/d Monday‐Friday) plus oxaliplatin (50 mg/m²/wk × 5)
Study: 23691062
Drug: Anti-tuberculosis therapy
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis therapy (ATT) with corticosteroids for IRIS treatment
Study: 17412546
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses compared to 0.01mmol/kg
Study: 14769684
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg)
Study: 11124753
Drug: Lithium-tagged yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium-tagged yogurt (500 mL) for 6 weeks
Study: 11124753
Drug: Lithium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium supplement (250 micromol/d) for 13 days
Study: 11124753
Drug: Half the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half the dose (125 micromol lithium/d) taken on each of 2 days
Study: 24501164
Drug: EMLA® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA® cream
Study: 9188873
Drug: EMLA® patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA® patch
Study: 8453559
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant interferon alfa‐2a and IL‐2 at a dose of 7.5 million units (MU)/m2 of interferon alfa‐2a and 1.5 MU/m2 of IL‐2, administered three and five times weekly for 4 weeks
Study: 2943106
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (150 mg trimestrially)
Study: 2943106
Drug: Ethinyl-oestradiol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl-oestradiol (1 mg daily for 5 days)
Study: 29337026
Drug: rhGH 4
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH 4 mg group
Study: 29337026
Drug: rhGH 8
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH 8 mg group
Study: 22353915
Drug: Education group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education group (Group II) - guardians received a pamphlet about how to help a child cooperate with the dentist during dental treatment.
Study: 20198451
Drug: 15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml/kg total body weight (TBW) of IV crystalloid solution (Group A)
Study: 20198451
Drug: 40 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml/kg total body weight (TBW) of IV crystalloid solution (Group B)
Study: 18668692
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of dexamethasone (1 mg/kg)
Study: 18668692
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of dexamethasone (0.15 mg/kg for 4 days)
Study: 18668692
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of dexamethasone
Study: 18668692
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of dexamethasone
Study: 10614835
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (initial dose of 2.0 g followed by a constant infusion at 20 mg/min)
Study: 7627244
Drug: Orlistat 30
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 30 mg/day
Study: 7627244
Drug: Orlistat 180
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 180 mg/day
Study: 7627244
Drug: Orlistat 360
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 360 mg/day
Study: 1512604
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (50 mg daily) and dipyridamole (400 mg daily)
Study: 6390998
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin in combination with dihydroergotamine
Study: 30328246
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 100 mg/day for 8 weeks
Study: 22278874
Drug: Antistick phospholipid
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antistick phospholipid solution (Electro Lube)
Study: 22278874
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antistick solution)
Study: 21084043
Drug: Contiflo ICON
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contiflo ICON 400 µg tablets
Study: 21084043
Drug: Flomaxtra XL
Normalized name: XL-888
DrugBank: XL-888 (DB12981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flomaxtra XL 400 µg tablets
Study: 15906662
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.7 mg/kg/d) plus rifampin (600 mg/d) for 2 weeks followed by fluconazole (400 mg/d) for 8 weeks
Study: 15906662
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.7 mg/kg/d) alone for 2 weeks followed by fluconazole (400 mg/d) for 8 weeks
Study: 10558970
Drug: Partially enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially enteric‐coated preparation of bovine immunoglobulins
Study: 1846057
Drug: lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (10 to 40 mg)
Study: 16785331
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 to 100 mg)
Study: 6354602
Drug: Ciramadol (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol (60 or 30 mg)
Study: 28527421
Drug: Lofexidine HCl
Normalized name: lofexidine HCl
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lofexidine HCl 3.2mg daily in four divided doses
Study: 24090266
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of ramelteon (melatonin agonist)
Study: 19623858
Drug: Mean Lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean Lung Dose (MLD)
Study: 15086698
Drug: Standard urticaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard urticaria therapies (corticosteroids, H2-antihistamines, H1-antihistamines, doxepin)
Study: 7714461
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (2.5 or 10 mg daily for 6 weeks)
Study: 27937064
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (Fp) delivered via MDPI 50, 100, 200, or 400 mcg twice daily for 12 weeks
Study: 27937064
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (Fp) delivered via DPI 250 mcg
Study: 24923372
Drug: Thiopentone sodium
Normalized name: Thiopentone sodium
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone sodium (5 mg/kg)
Study: 17131169
Drug: Solifenacin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (both doses)
Study: 11603453
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (10 mg/kg) 4 hours preoperatively
Study: 12520569
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no steroid administration)
Study: 9847641
Drug: 0.5% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% tetracaine drops and intravenous fentanyl and propofol with continuous sedation (Group I)
Study: 9847641
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine in the retrobulbar space and hypnotic doses of intravenous propofol (Group II)
Study: 2634902
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg twice daily)
Study: 712981
Drug: Megavitamin combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megavitamin combination
Study: 25684006
Drug: Fentanyl group
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl group (0.5% hyperbaric bupivacaine 0.2 mL + fentanyl 20 μg + 5% dextrose 1.4 mL)
Study: 25684006
Drug: Sufentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil group (0.5% hyperbaric bupivacaine 0.2 mL + sufentanil 5 μg + 5% dextrose 1.7 mL)
Study: 17931382
Drug: BNP plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP plasma levels low (< 100 pg mL(‐1))
Study: 17931382
Drug: BNP plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP plasma levels intermediate (100-500 pg mL(‐1))
Study: 17931382
Drug: BNP plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP plasma levels high (> 500 pg mL(‐1))
Study: 15230644
Drug: Tegaserod 6mg
Normalized name: tegaserod 6 MG
DrugBank: Tegaserod (DB01079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tegaserod 6mg twice daily
Study: 9219678
Drug: Hyalgan (500-730
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyalgan (500-730 kDa molecular weight), three cycles of three intra-articular injections (once a week during 2 weeks) every 3 months
Study: 8424294
Drug: Metoclopramide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (1 mg.kg‐1 i.v. preoperatively, followed by 1.5 mg.kg‐1 infusion over 9 h)
Study: 29614243
Drug: HP/TAZ lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP/TAZ lotion (halobetasol propionate 0.01% plus tazarotene 0.045%)
Study: 27037169
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 2% Carbocaine lidocaine gel with 1 mL 0.9% saline (group 1)
Study: 27037169
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL 5% NaHCO3 solution (group 2)
Study: 24997651
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g dose of tranexamic acid (Group 1)
Study: 24997651
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg dose of tranexamic acid (Group 2)